Dr. Eggington co-founded the Center for Genomic Interpretation (CGI) in 2016, which became a nonprofit organization in 2017, with the mission to drive quality in clinical genetics. To accomplish its mission, CGI provides a variety of services to health insurers, laboratories, clinicians and patients. Dr. Eggington is an expert in the initial classification of novel clinical genetic variants, high throughput literature curation, as well as the accurate re-classification of Variants of Uncertain Significance (VUS) through optimized research methods. Dr. Eggington has directed variant classification and reclassification programs at Myriad Genetics, Courtagen, and 23andMe. Read her full bio.

Interview with Julie Eggington of Center for Genomic Interpretation

Q1a: Together with Robert Burton you founded the Center for Genomic Interpretation (CGI), a non-profit organization. Can you tell us more about CGI and the mission behind it?

A: CGI’s mission is to drive quality in clinical genetics and genomics. CGI works primarily with laboratories, health insurance payers, clinicians, and patients/consumers. CGI provides tailored services to educate and support these stakeholders so that more patients/consumers get clinically valid and accurate results.

Q1b: Why is CGI a non-profit organization instead of a for-profit organization? What is the idea behind it?

A: CGI is a 501(c)(3) deep tech humanitarian organization founded in 2017. As an independent and non-profit organization, CGI provides tailored services at reasonable prices to customers who are looking for unbiased technical support and education in the very niche area of commercial clinical genetics and genomics. Since CGI charges for services that are in line with its mission, CGI’s basic operations are self-sustained. To date, CGI has provided services to laboratories and health insurance payers, though CGI is expanding its services to support government policy makers, clinicians and patients/consumers.

CGI’s donor fundraising efforts focus on preparing for CGI’s much larger and longer term goal of making accurate clinical genetic variant classification and reclassification pre-competitive. CGI aims to provide just-in-time variant classification services at scale to commercial and academic laboratories at low cost, so that all labs are capable of providing the highest quality variant classifications and reclassifications to patients and consumers.

Q: What excites you about your work at CGI?

A: I am most excited about the positive patient impact we have in our work. By helping the genetics and genomics labs and health insurance payers implement improved quality initiatives, we get to help many thousands, if not millions, of patients.

Q: What organizations has CGI worked with in the context of genomic data interpretation?

A: We have non-disclosure agreements with all of the commercial labs that we help with genetic variant classification. Most of the labs we currently serve are medium to high volume laboratories wanting to supplement their current pipelines. Though we also support several startup companies.

We have also started helping health insurers on some very particular genomic data interpretation challenges related to true and false positive variant interpretations, where true positives may lead to a precision therapy. For example, RPE65 pathogenic variant interpretations may result in treatment with Luxturna, costing close to one million dollars per treatment.

Also, due to a recent press release made by Blue Shield of California (BSCA), we can now say that BSCA is partnering with CGI on CGI’s ELEVATEGenetics initiative, which is an initiative to provide more transparent and standardized laboratory quality metrics to stakeholders.

Q: Can you tell us more about a specific example?

A: Regarding variant classification, many laboratories have optimized their variant classification work flows to decrease false negative interpretation rates. This often results in the unintended consequence of higher false positive interpretation rates, which have contaminated ClinVar. ClinVar is the most widely used public variant classification database in the USA. False positive variant interpretations can sometimes contribute to erroneous medical procedures and therapies, so many laboratories double check the data behind the classification claims made in ClinVar before using the classifications. Sometimes these labs that are checking out ClinVar classifications will disagree with pathogenic or likely pathogenic consensus classifications. Before issuing a non-consensus report, these labs often ask CGI to independently assess the classifications on variants to see if CGI agrees or disagrees with the consensus classification. CGI’s stringent variant classification and reclassification protocols are well suited for this fact-checking work.

Q: Variant data interpretation has its challenges. How can we improve the interpretation of variant data in that are used in the clinic to diagnose a disease or make treatment patient treatment decisions?

A: CGI views its nonprofit business model as the operational solution to bring accurate variant classifications and reclassifications into the clinic. Accurate variant classification must be evidence based, and clinical scientists must guard against the heavy use of research data which is contaminated by ascertainment bias and publication bias. CGI has developed its own stringent evidenced based process that allows it to provide variant classification as a service to labs for any genes associated with monogenic disease. Also, excellent professional and academic consortia groups continue to publish updates to variant interpretation protocols.

Q: What are some of the biggest challenges the industry is currently facing when it comes to genomic data interpretation, and how will we overcome these challenges?

A: For all but the highest volume boutique commercial laboratories, the cost of accurate variant classification for many sequencing tests exceeds the reimbursement value of those tests. Some labs use venture capital funds to close this gap, and/or take low quality shortcuts to lower costs, or simply stop offering certain genetic tests. CGI is working to fix this in two ways:

  1. CGI is educating health insurers on the true costs of high quality genetic tests, and the benefits of using higher quality tests over lower quality tests. CGI’s ELEVATEGenetics initiative is part of this effort, providing needed transparency to laboratory quality metrics.
  2. CGI is fundraising in order to build out its larger scale and lower cost accurate variant classification service. In this way, CGI will act as a central nonprofit service, providing accurate variant classifications and reclassifications to all labs at a significantly reduced price through a just-in-time model. Due to the scale, and being able to serve many laboratories in a noncompetitive way, CGI will achieve an economy of scale unachievable by any single laboratory, thus driving costs of variant classification down for everybody.
Q: Who is mostly affected by these challenges?

A: Patients are most affected. In some hereditary diseases the false positive rate due to over-interpretation of sequence variants may currently exceed one in every two positive reports. These patients may end up being treated for diseases they do not have, while the diagnostic journey to find their true disease is abandoned.

In rarer cases, false positive variant interpretations may lead to erroneous fetal terminations. This was the case in the early 2000’s with the CFTR I148T variant which was included on the ACMG and ACOG panethnic panel of CFTR pathogenic variants. The variant was later demonstrated to be an interpretation false positive, and is now known to be a somewhat frequent and benign variant in the Indian population.

Q: Is there anything else you would like to share with the PMWC audience?

A: Much of precision medicine relies on accurate interpretation of genetics and genomics data. Unless we are able to improve the current quality of genetic variant interpretation in the industry, precision medicine will not advance at the rate we all hope it will. CGI is dedicated to fixing quality and accuracy problems in clinical genetics and genomics. CGI is always thrilled to receive donations in order to help patients get accurate results, and to help both established and start up commercial companies succeed with high quality offerings. So please support the Center for Genomic Interpretation in its mission to drive quality in clinical genetics.

Interview with Shannon J. McCall of Duke University

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend?

A: After several years of the promise of precision medicine and abundant clinical trial work, the recent FDA approval of solid-tumor-agnostic therapies dependent on molecular biomarkers has catapulted genomic/precision medicine into the standard-of-care for late stage cancer.

Read More

Interview with Tao Chen of Paragon Genomics, Inc.

Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling for clinical Dx. How soon, do you think, will we see accelerated growth and what can we expect?

A: For whole genome sequencing to be a reliable clinical tool, it will largely depend on the cost of sequencing the genome and our ability to interpret the data.

Read More

Call for Action: The Time is Now for Patient Data Interoperability

The use of new technologies can provide breakthrough benefits for both patients and providers. However, with increased sharing comes increased risks to the security and privacy of patient data. Currently data is being accumulated across many organizations and initiatives but is often either siloed or simply not accessible. Researchers suggest that patient education tactics can help quell security concerns during patient data sharing.

Read More

Interview with Andrew Magis of Arivale

Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling. How soon, do you think, will we see what kind of accelerated growth?

A: I think the acceleration has already begun. Large sequencing projects such as NHLBI Trans-omics for Precision Medicine (TOPMed) and NIH All of Us are sequencing 150,000 and 1 million individuals, respectively.

Read More

Interview with Emily Leproust of Twist Bioscience

Q: NGS is enhancing patient care through improved diagnostic sensitivity and more precise therapeutic targeting. Prominent examples include cystic fibrosis and cancer. What other clinical areas NGS will most likely to change the standard-of-care in the near future?

A: Preventative medicine – using genetic data to identify traits that have the potential to cause harm in the future.

Read More

Interview with Michael Phelps of UCLA

Q: You invented the PET scanner that changed the lives of millions of patients with cancer, brain and heart diseases. What are the potential benefits to patients of combining PET with radio-ablation technologies?

A: PET provides imaging assays of the biology of disease in many diseases today.

Read More

Interview with Daniela Ushizima of Lawrence Berkeley National Lab

Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are your thoughts?

A: I really hope that human physicians will not be replaced by machines in the foreseeable future.

Read More

Interview with Amy Compton-Phillips of Providence St. Joseph Health

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend? What technological advancements are driving this change?

A: Genomic medicine is poised to move quickly from the research realm into integration with healthcare delivery, but there is always a time lapse between technology advances and what we do with those advances.

Read More

Interview with James Taylor of Precision NanoSystems

Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?

A: Patients are already receiving treatment using novel gene and cell therapies.

Read More

Interview with Julie Eggington of Center for Genomic Interpretation

Q: Together with Robert Burton you founded the Center for Genomic Interpretation (CGI), a non-profit organization. Can you tell us more about CGI and the mission behind it?

A: CGI’s mission is to drive quality in clinical genetics and genomics. CGI works primarily with laboratories, health insurance payers, clinicians, and patients/consumers.

Read More

Interview with Deven McGraw of Ciitizen

Q: Patient healthcare data aggregation and analysis is seen as both the panacea for tremendous breakthroughs in precision medicine and as one of its biggest challenges. Are both true and how so?

A:Yes, both are true. Achieving breakthroughs in precision medicine will require a lot of data – and yet it is often difficult for researchers to amass all of the data needed to advance precision medicine discoveries.

Read More

Breaking News: CMS Takes Actions to Lower Prescription Drug and Other Healthcare Costs – Seema Verma Speaking @PMWC19

The cost of healthcare has been rising at an annual rate of 7% be it company-sponsored health insurance, public insurance such as Medicare and Medicaid, or private insurance. As such, healthcare was top of mind for many individuals this 2018. In the November midterm election many items related to healthcare such as Medicaid expansion, provider pay and indirect effects on the Affordable Care Act could be found on the ballot.

Read More

Did You Catch All 6 of These Big Genomic Medicine Headlines in Recent Weeks?

Genomic sequencing, the driver of modern genomic medicine has come a long way in a short time, and its potential to continue driving innovations in precision medicine is enormous. PMWC 2019 Silicon Valley Jan. 20-23 in the Santa Clara Convention Center will focus on topics that are in the headlines and on everyone’s minds, in NGS and in precision medicine.

Read More

Interview with Christopher Hopkins of Nemametrix

Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?

A: We should all be working towards integrating these technologies into routine patient care as quickly as possible, because genomic medicine has the capacity to make profound impacts now.

Read More

Interview with Kristine Ashcraft of YouScript

Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?

A: It’s certainly hard to predict, but our goal is to see precision medicine tools in the hands of most providers in the next five years.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 16th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 20-23, 2019. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!